Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 4/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.62 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.62 |
| ▸ | HTR1A | P08908 | 3/20 | 0.62 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.62 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.62 |
| ▸ | DRD1 | P21728 | 3/20 | 0.62 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.62 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.62 |
| ▸ | DRD3 | P35462 | 3/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | KDM1A | O60341 | 1/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Perimetazine SCHEMBL29406905 | 1.00 | PTGS1 (0.62) | PTGS1CYP2D6CHRM2HTR1AADRA2A | |
| SCHEMBL14540176 | 0.90 | CYP2D6 (0.62) | PTGS1CYP2D6CHRM2HTR1AADRA2A | |
| SCHEMBL11686271 | 0.88 | CYP2D6 (0.58) | PTGS1CYP2D6CHRM2HTR1AADRA2A | |
| SCHEMBL11686277 | 0.87 | CYP2D6 (0.56) | PTGS1CYP2D6CHRM2HTR1AADRA2A | |
| SCHEMBL11686974 | 0.79 | CYP2D6 (0.74) | PTGS1CYP2D6CHRM2HTR1AADRA2A | |
| SCHEMBL14340247 | 0.77 | LMNA (0.46) | PTGS1CYP2D6CHRM2HTR1AADRA2A | |
| Dextromepromazine SCHEMBL23859840 | 0.77 | CYP2D6 (1.00) | PTGS1CYP2D6CHRM2HTR1AADRA2A | |
| Levomepromazine SCHEMBL6944555 | 0.77 | CYP2D6 (1.00) | PTGS1CYP2D6CHRM2HTR1AADRA2A | |
| Levomepromazine SCHEMBL25462 | 0.77 | CYP2D6 (1.00) | PTGS1CYP2D6CHRM2HTR1AADRA2A | |
| Levomepromazine SCHEMBL8762418 | 0.77 | CYP2D6 (1.00) | PTGS1CYP2D6CHRM2HTR1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9757376-B2 | Pharmaceutical compositions | GM PHARMACEUTICALS, INC. (US) | 2017-09-12 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| CN-1997400-A | Conjugated psychotropic drugs and uses thereof | UNIV RAMOT (IL) | 2007-07-11 | — | — | CN | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| EP-1727566-A2 | CONJUGATED PSYCHOTROPIC DRUGS AND USES THEREOF | Ramot at Tel Aviv University Ltd. (IL) | 2006-12-06 | — | — | EP | claimed |
| EP-1641446-A1 | PHARMACEUTICAL COMPOSITIONS INCLUDING AN ANTIHISTAMINE AND A STIMULANT AND USE THEREOF | Pediamed Pharmaceuticals, Inc. (US) | 2006-04-05 | — | — | EP | claimed |
| WO-2005092392-A2 | CONJUGATED PSYCHOTROPIC DRUGS AND USES THEREOF | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2005-10-06 | — | — | WO | claimed |
| WO-2004112771-A1 | PHARMACEUTICAL COMPOSITIONS INCLUDING AN ANTIHISTAMINE AND A STIMULANT AND USE THEREOF | PEDIAMED PHARMACEUTICALS, INC. (US) | 2004-12-29 | — | — | WO | claimed |
| US-20040259809-A1 | Pharmaceutical compositions including an antihistamine and a stimulant and method of use thereof | PEDIAMED PHARMACEUTICALS, INC. | 2004-12-23 | — | — | US | claimed |
| US-20040242570-A1 | Conjugated psychotropic drugs and uses thereof | BAR-ILAN UNIVERSITY (IL) | 2004-12-02 | — | — | US | claimed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-11191719-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2021-12-07 | — | — | US | disclosed |
| US-10987365-B2 | Compositions and methods for the treatment of pain | GM PHARMACEUTICALS, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20020102215-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-6331289-B1 | ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED | NYCOMED IMAGING AS (NO) | 2001-12-18 | — | — | US | disclosed |
| US-6264917-B1 | MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242570-A1 | Conjugated psychotropic drugs and uses thereof | SLC18A2, SLC6A3, SLCO1B3 | PTGS1 3095/4885CYP2D6 109/4885CHRM2 1673/4885 |
| US-20020102215-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | PTGS1 2981/4885CYP2D6 4855/4885CHRM2 4525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.